Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

oellex, the Company's lead compound, a PRM (progesterone receptor modulator) has recently completed a successful U.S. three-month Phase 2 clinical trial for the treatment of uterine fibroids, a condition that affects numerous women of childbearing age in the United States and results in a significant number of hysterectomies each year. Proellex has recently completed a six-month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million women in the United States and Canada. Androxal(TM), the Company's other program in late clinical development, is designed to restore normal testosterone production by the testes in men and has recently completed a six-month U.S. non-pivotal Phase 3 clinical trial for the treatment of testosterone deficiency due to secondary hypogonadism. According to industry sources, approximately 13 million men in the United States experience testosterone deficiency. The Company is planning meetings with the FDA for all three programs to lay out the remaining clinical program pathway required before a New Drug Application may be submitted for each product candidate.

For more information, please visit the Company's website at http://www.reprosrx.com.

Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to have success in the clinical development of its technologies, the timing of enrollment in such clinical studies and the accuracy of such studies, Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, and Repros' Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... , July 30, 2015 Takeda Pharmaceutical ... study to fulfill the post-marketing commitment and submissions ... Pan European Multi-Database Bladder Cancer Risk Characterization Study ... cohort study, conducted in four European countries, for ... up to 10 years of follow-up. Findings demonstrate ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... ... Reportlinker.com announces that a new market research report ... Markets for Breast Biopsy Devices 2009 , ... markets for breast biopsy devices includes the spring ...
... , NATICK, Mass. and LONDON, Nov. ... ) today announced that it has received 510(k) clearance ... CE Mark approval to market its WallFlex® Fully Covered ... (obstructions) caused by tumors in patients with resectable or ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... As ... programs, the activity of recruiting patients becomes a serious challenge. Because of growing competition, ... program to patients within the local community. , The team at Wound ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... The connection between a healthy ... and women. The loss of a full head of hair can have a devastating ... how a person is perceived in the work place, the consequences of hair loss are ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud to ... San Diego, California’s Gaslamp Quarter Plaza for five years this September. , The ... the area for any suspicious activity. These cameras are in place to provide ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... into one of the largest, family-owned low cost service and repair companies. For ... applications, as well as growing their company to meet the demands of the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Beachside Nursing Center Releases New Video 2
... diseases, bringing in hope where ... there is none!, ... resigned to a life of pain with Rheumatoid Arthritis is healthy,and normal ... my,Good Shepherd, Jesus and His own good shepherd, Dr. Omar, have rescued ...
... DCGN ) today announced that it will host ... the Lazard Capital Markets 4th Annual,Healthcare Conference., The ... Tuesday, November,27 at the Palace Hotel, New York City. ... deCODE,s website, http://www.decode.com, and those,interested in listening ...
... Contaminated water could boost child,s cancer risk, study finds ... women exposed to arsenic-contaminated water during pregnancy have gene ... diseases later in life, a Massachusetts Institute of Technology ... work is the first documentation of widespread genetic ...
... AIDS Treatment Provision on World AIDS ... ... to an,increasing need for more effective AIDS treatments in India and recent,high-profile ... Organization (NACO) and Health Minister A.,Ramadoss will announce the rollout of lifesaving ...
... individual has on receiving his paycheque depend critically on ... comes from an experiment conducted by economists and brain ... subjects in pairs, asking them to perform a simple ... tomographs, the researchers examined the volunteers, brain activity throughout ...
... also encourages midday sleepiness, experts say, , , THURSDAY, Nov. ... heads after the Thanksgiving feast aren,t rare, and experts ... during the holiday. , It may have to do ... in tryptophan -- a chemical known to promote sleepiness, ...
Cached Medicine News:Health News:Stem Cells- Dr. Omar Gonzalez' Therapy for all Ills! 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 3Health News:Money motivates -- especially when your colleague gets less 2Health News:Money motivates -- especially when your colleague gets less 3Health News:There's More Than Turkey Behind Holiday Yawns 2
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... an X-ray contrast medium for ... for: angiography, urography, phlebography and ... of the basal cisterns, following ... cholangio (pancreato) graphy (ERC(P)), herniography, ...
... (gadobenate dimeglumine) is a paramagnetic MRI contrast ... with gadobenate, a chelating agent that forms ... godolinium ion. It is salified with meglumine ... with all the physico-chemical features typical of ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
Medicine Products: